What question did this study set out to answer?

The research aims to evaluate the effects of Lactococcus lactis LMG 27352 supplementation on cardiometabolic risk factors in obese patients.

February 2, 2026

Supplementation With Lactococcus lactis LMG 27352: Lack of Beneficial Effects on Cardiometabolic Risk in Obese Patients Without Concomitant Dietary Intervention—A Randomized, Triple-Blind, Placebo-Controlled Clinical Trial

Key Points

The research aims to evaluate the effects of Lactococcus lactis LMG 27352 supplementation on cardiometabolic risk factors in obese patients.
Conducted a randomized, triple-blind, placebo-controlled clinical trial.
Included obese individuals without dietary intervention.
Compared effects of L lactis supplementation versus placebo.
Demonstrated limited clinical efficacy of probiotic supplementation on metabolic disorders.
Showed that dietary intake of sodium and carbohydrates may counteract potential benefits.

Abstract

The findings of this study suggest limited clinical efficacy of L lactis LMG 27352 supplementation in metabolic disorders related to obesity under the conditions investigated. These results underscore the critical influence of dietary patterns, particularly sodium and carbohydrate intake, which may have modulated or counteracted any potential benefits of the probiotic strain.

Supplementation With Lactococcus lactis LMG 27352: Lack of Beneficial Effects on Cardiometabolic Risk in Obese Patients Without Concomitant Dietary Intervention—A Randomized, Triple-Blind, Placebo-Controlled Clinical Trial

Key Points

Abstract

Cite This Study